Frankincense (Boswellia)
Frankincense is the gum resin of the genus Boswellia; studies in humans show improvements especially in joint complaints and inflammation markers 12672938.
We evaluated 215 human studies on Frankincense (Boswellia), including 94 randomised controlled trials and 17 meta-analyses or systematic reviews; the controlled studies include 7,221 participants in total. As of 9 October 2026.
1. What Is Frankincense (Boswellia)? Occurrence, Origin and Forms
Frankincense is the resin of trees of the genus Boswellia in the family Burseraceae. It has long been used as incense and is a customary remedy in Ayurvedic and traditional medicine in India and the Middle East. Studies mostly examine an extract of the resin that is standardised for its content of boswellic acids.
Boswellia species grow in dry regions of India, Africa and the Arabian Peninsula; Boswellia serrata comes from India, Boswellia sacra from the Arabian Peninsula. Cultivation is limited, and most of the resin comes from wild stands.
The resin is obtained by cutting the bark of the trunks; the sap that runs out hardens in the air into lumps of resin. Human studies mainly examine extracts with a stated content of boswellic acids, as well as the resin itself, powdered preparations, and topical ointments or oils.
Forms and Preparations Studied
- Resin in lumps, as used for incense
- Powder made from the resin
- Extract with a stated content of boswellic acids
- Capsules or tablets containing resin or extract
- Ointments and oils for topical use
- Essential oil from the resin
Not covered on this page:
- Myrrh, the resin of Commiphora species, even though the two are often used together as incense
- Incense blends for ritual use that contain additives besides the resin
- Other resins and tree exudates that are also sold under the name frankincense
2. What Does Frankincense (Boswellia) Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Joints and musculoskeletal system | mostly improved | high | 6 meta-analyses · 15 controlled · 29 other | 1,002 |
| Inflammatory processes | mostly improved | high | 1 meta-analyses · 15 controlled · 21 other | 1,035 |
| Gut | mixed | moderate | 1 meta-analyses · 5 controlled · 9 other | 328 |
| Skin | mixed | moderate | 0 meta-analyses · 5 controlled · 4 other | 159 |
| Respiratory tract | mostly improved | low | 0 meta-analyses · 1 controlled · 5 other | 47 |
| Tolerability and safety | mostly no difference | unclear | 0 meta-analyses · 3 controlled · 60 other | 199 |
| Other investigations | mixed | high | 2 meta-analyses · 28 controlled · 53 other | 1,582 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Frankincense (Boswellia), Joints and Musculoskeletal System: Human Studies
For knee osteoarthritis, Boswellia showed improvements in pain, stiffness and function in several controlled studies and meta-analyses 12672938. The WOMAC total score also improved in controlled studies 2938. The distance in the six-minute walk test increased under Boswellia extract 3843, explicitly demonstrated versus placebo in one study 43. In two placebo studies, imaging findings at the knee under Boswellia extract showed more cartilage and a wider joint space 43 or fewer bone spurs (osteophytes) 62. A meta-analysis on dietary supplements for osteoarthritis found short-term pain relief for Boswellia 16. The findings come predominantly from ingested extracts; applied to the knee, an oily frankincense extract solution also lowered WOMAC and pain scores more than placebo 75. A meta-analysis found no confirmed difference in WOMAC and pain across all comparisons, but lower WOMAC scores versus placebo 4. Solid lipid particles and a standard extract from Boswellia did not differ in WOMAC and pain 79. Ayurvedic mixtures with ginger had effects in knee osteoarthritis similar to glucosamine or celecoxib 24. Mixtures with turmeric relieved acute muscle pain after exercise more than placebo 2526; these results do not apply to frankincense alone. The strength of evidence is high; however, most studies are small and short, and larger and longer studies are still pending.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Zhang et al. 2025 | meta-analysis · 4,599 participants | Boswellia (form not specified); vs. Placebo | WOMAC pain: improved (MD = 10.58, 95% CI: 6.45 to 14.78, p < 0.05); WOMAC stiffness: improved (MD = 9.47, 95% CI: 6.39 254 to 12.74, p < 0.05); WOMAC function: improved (MD = 14.00, 95% CI: 7.74 to 20.21, p < 0.05) |
| 2 Del et al. 2017 | systematic review · 1,741 participants | Oral herbal medicines, including Boswellia serrata; vs. placebo or valdecoxib | pain and physical function: improved |
| 3 Inprasit et al. 2026 | meta-analysis · 1,633 participants | Boswellia serrata (BS) and mixture with Curcuma longa; vs. Placebo and other intervention groups | WOMAC pain, stiffness, and knee function: improved (significant improvement); VAS pain (modified CL formulations): improved (SMD: -2.82; 95 %CI: -5.30 to -0.33) |
| 4 Dalmonte et al. 2024 | meta-analysis · 1,185 participants | Phytoextracts from the oleogum resin of the Boswellia genus; vs. Placebo, negative or positive control | WOMAC score: no difference (p = 0.0865); VAS score: no difference (p = 0.3966); WOMAC score versus placebo: improved |
| 5 Bannuru et al. 2018 | meta-analysis · 1,009 participants | Boswellia and curcuminoid formulations; vs. Placebo or NSAIDs | Pain relief: improved; Functional improvement: improved |
| 6 Dubey et al. 2024 | systematic review · 712 participants | standardized Boswellia serrata extract (Aflapin) versus other BS extracts; vs. control therapy (placebo or other BS extracts) | VAS pain: improved (MD: -10.71; p<0.00001); Lequesne Functional Index (LFI): improved (MD: -2.99; p<0.00001); WOMAC pain: improved (MD: -10.69; p<0.0001) |
| 7 Yu et al. 2020 | meta-analysis · 545 participants | Boswellia serrata or its extract; recommended treatment duration at least 4 weeks; vs. Placebo or western medicine | VAS pain: improved (WMD -8.33; 95% CI -11.19, -5.46; P<0.00001); WOMAC pain: improved (WMD -14.22; 95% CI -22.34, -6.09; P = 0. 0006); WOMAC stiffness: improved (WMD -10.04; 95% CI -15.86, -4.22; P = 0. 0007) |
| 12 Efferth et al. 2022 | review | Frankincense (Boswellia spp.) and its phytochemical ingredients; vs. no uniform comparison reported | efficacy against osteoarthritis: improved |
Further studies in this area: 16 18 29 37 38 43 45 46 49 53 54 59 62 75 76 79 83 87 88 92 94 96 97 98 99 100 106 107 109 121 136 140 142 143 146 147 152 153 158 159 161 162
Frankincense (Boswellia) and Inflammatory Processes: Human Studies
In knee osteoarthritis, hs-CRP fell more under Boswellia extracts than under placebo 2943; after stroke and in COVID-19, TNF-α and IL-8 fell under boswellic acids 4491. In Parkinson's disease, several inflammatory messengers fell under boswellic acids compared with baseline 55. Solid lipid particles from Boswellia lowered pro-inflammatory cytokines, while under a standard extract they increased 79. A mixture of methylsulfonylmethane and boswellic acids lowered pain and the consumption of anti-inflammatory agents similarly to glucosamine, with a trend in favor of the mixture 35. In spondylitis complaints, NLRP3 inflammasome and IL-1β fell under a Boswellia extract and its mixture with curcumin; the mixture acted more strongly 37. In a randomized study, a mixture of boswellic acids, collagen, MSM and vitamin C/D3 reduced the synovitis area on MRI more than glucosamine with chondroitin 48. Predominantly standardized extracts with a stated content of boswellic acids were investigated; it remains open how closely the lowered inflammation values are related to the benefit in complaints.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 12 Efferth et al. 2022 | review | Frankincense (Boswellia spp.) and its phytochemical ingredients; vs. no uniform comparison reported | inhibition of leukotriene, COX-1/2 and 5-LOX synthesis: improved |
| 18 Fusini et al. 2016 | systematic review | Boswellic acid among other nutraceuticals; vs. Use of various nutraceuticals | Role in inflammation: unclear |
| 21 Di et al. 2013 | systematic review | Food supplements with Boswellia serrata Roxb. | Efficacy for pain/inflammatory conditions: improved |
| 29 Jayaram et al. 2025 | randomised controlled · 150 participants | Boswellia serrata extract (BOSMAX®); daily (amount not stated); 90 days; vs. Placebo | TNF-α: improved (-104.75 ng/L); hs-CRP: improved (-5.67 ng/mL) |
| 37 Mamatha et al. 2025 | randomised controlled · 105 participants | F-BSE: bioavailability-enhanced full-spectrum Boswellia serrata oleo-gum resin extract; C-BSE co-delivered with curcumin; 400 mg/day; 28 days; vs. Placebo and F-BSE versus C-BSE, three arms | NLRP3 inflammasome levels: improved (by days 14 and 28); IL-1β levels: improved (by days 14 and 28) |
| 38 Majeed et al. 2024 | randomised controlled · 105 participants | Boswellin® Super, standardized Boswellia serrata gum resin extract, 30% 3-acetyl-11-keto-β-boswellic acid; 150 mg or 300 mg twice daily; 90 days; vs. placebo tablet | serum TNFα, hs-CRP, IL-6: improved |
| 43 Kumar et al. 2025 | randomised controlled · 80 participants | SN13108F (Aflapin), standardized Boswellia serrata gum resin extract; 100 mg/day; 180 days; vs. placebo | high-sensitivity C-reactive protein: improved (p < 0.001); matrix metalloproteinase-3: improved (p < 0.001); Fibulin-3: improved (p < 0.001) |
| 44 Baram et al. 2019 | randomised controlled · 80 participants | Boswellic acids (BAs), main bioactive compounds of Boswellia sp. resin, as supplementary therapy; 1-month follow-up; markers after 7 days; vs. Placebo, double-blind, randomized | Plasma TNF-α: improved (significantly decreased in BA group after 7 days); Plasma IL-1β: improved (significantly decreased in BA group after 7 days); Plasma IL-6: improved (significantly decreased in BA group after 7 days) |
Further studies in this area: 46 49 51 55 59 62 63 64 79 88 91 105 106 107 110 112 113 115 116 119 134 144 146 147 148 150 152 156 162
Frankincense (Boswellia) and Gut: Human Studies
A systematic review saw evidence of efficacy of Boswellia resin extract in Crohn's disease, mostly from small individual studies 14; another found the best evidence in Crohn's disease for wormwood 19. A randomized controlled study in patients with Crohn's disease in remission found no difference in remission rate and time to relapse 36. In collagenous colitis, remission under Boswellia extract was more frequent per protocol than under placebo, with no confirmed difference in the analysis of all participants 68. In irritable bowel syndrome, participants under Casperome, a Boswellia serrata extract in lecithin form, had lower scores for almost all complaints and needed rescue medication less often than under standard treatment 51. In a non-randomized study, complaints improved in all groups, but fewer participants under Casperome needed medical help 84. In acute diarrhea, adults under Boswellia extract in lecithin form recovered faster than under placebo and had fewer bowel movements, abdominal pain and nausea 61. A mixture of turmeric and Boswellia extract in lecithin form, together with a low-FODMAP diet, reduced bloating and abdominal pain more than the diet alone 5260. The intestinal studies are mostly small, and several tested mixtures with turmeric; it remains open which form works in which intestinal disease.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 14 Holleran et al. 2020 | review | Boswellia serrata resin extract; vs. Placebo in double-blind randomised trials | Evidence of efficacy in Crohn's disease: improved |
| 19 Langhorst et al. 2015 | systematic review | Boswellia serrata among other CAM agents; vs. Randomized and controlled trials | Efficacy of herbal therapy in IBD: unclear |
| 36 Holtmeier et al. 2011 | randomised controlled · 108 participants | Boswellia serrata extract Boswelan (PS0201Bo), capsules; 3×2 capsules/day of 400 mg each; 52 weeks; vs. Placebo, double-blind, randomized, parallel | Proportion in remission throughout 52 weeks: no difference (59.9% versus 55.3% (P=0.85)); Time to relapse: no difference (171 days versus 185 days (P=0.69)); CDAI, IBDQ and laboratory inflammation measurements: no difference |
| 51 Riva et al. 2019 | randomised controlled · 69 participants | lecithin-based delivery form of boswellic acids from Boswellia serrata (Casperome®); one tablet/day; 6 months; vs. standard management: diet and, if needed, hyoscine butylbromide or papaverine hydrochloride + Atropa belladonna extract | mean score values for almost all self-assessed IBS symptoms: improved; need for rescue medications: improved (significantly lower need for rescue medications) |
| 61 Giacosa et al. 2022 | randomised controlled · 49 participants | Lecithin-based delivery form of Boswellia serrata extract (CASP); 250 mg for 5 days; 5 days; vs. placebo, randomized double-blind | time to become healthy with stoppage of diarrhea: improved (3.08 vs. 4.44 days: p-value < 0.0001); probability of recovering sooner: improved (80.2%); number of stools over time: improved (β = −0.17, p-value < 0.0001) |
| 68 Madisch et al. 2007 | randomised controlled · 31 participants | Boswellia serrata extract (BSE), oral; 400 mg three times daily; 6 weeks double-blind, then 6 weeks open-label BSE; vs. placebo, randomized, double-blind, multicenter | clinical remission after 6 weeks (per protocol): improved (63.6%; 95%CI, 30.8-89.1 vs 26.7%, 95%CI, 7.7-55.1; p=0.04); clinical remission after 6 weeks (intention-to-treat): no difference (43.8% vs 26.7%, p=0.25); histology: no difference (no effect on histology) |
| 84 Belcaro et al. 2017 | controlled · 71 participants | Boswellia serrata extract as lecithin-based delivery form (Casperome®); 4 weeks; vs. hyoscine butylbromide; papaverine HCl + belladonna extract | IBS symptoms (abdominal pain, bowel movements, meteorism, cramps): no difference (improved during the observational period); subjects needing medical attention: improved (significantly decreased only in Casperome®-supplemented group) |
| 110 Pellegrini et al. 2016 | cohort study · 43 participants | Casperome®, lecithin-based Boswellia serrata extract; 4 weeks; vs. no supplementation (n = 21) | Diffuse intestinal pain: improved; Evident and occult blood in stools: improved; Bowel movements and cramps: improved |
Further studies in this area: 119 133 137 145 150 163 164
Frankincense (Boswellia) and Skin: Human Studies
A review reports on clinical studies with frankincense preparations in psoriasis and erythematous eczema 12. In second-degree burns, wounds healed under a preparation of Boswellia carteri about as quickly as under silver sulfadiazine cream 58. A cream with boswellic acids improved roughness, fine lines and elasticity in women with photoaged facial skin and reduced sebum production, each more than the base cream on the other half of the face 7172. In a randomized study, a boswellic acid cream with lecithin improved scaling and redness in psoriasis as well as itching and redness in eczema more than placebo 82. The skin studies are small and tested very different preparations; it remains open which preparation is suitable for which skin condition.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 12 Efferth et al. 2022 | review | Frankincense (Boswellia spp.) and its phytochemical ingredients; vs. no uniform comparison reported | efficacy against psoriasis and erythematous eczema: improved |
| 42 Faraji et al. 2021 | randomised controlled · 90 participants | Sitz-bath with Boswellia carteri extract; 10-min sitz-bath twice a day; 1 week; vs. myrrh extract sitz-bath and betadine sitz-bath | episiotomy wound healing (REEDA scale): no difference (p > 0.05) |
| 58 Badr et al. 2023 | randomised controlled · 54 participants | sterilized topical formulation containing 40% Boswellia carteri; follow-up until day 17; vs. silver sulfadiazine cream 1% | mean healing time: no difference (10.73 (9.23-12.23) days); healing index on day 17: no difference (reached 1) |
| 71 Calzavara-Pinton et al. 2010 | randomised controlled · 15 participants | cream containing 0.5% boswellic acids from Boswellia serrata; once daily, 0.5% BAs; 30 days; vs. placebo cream, split-face, randomized double-blind | Dover's global score for photoaging: improved (Significant improvements); tactile roughness: improved (Significant improvements); fine lines: improved (Significant improvements) |
| 81 Togni et al. 2015 | randomised controlled | Cream containing boswellic acids (Bosexil), Boswellia serrata; vs. Placebo cream | erythema grade: improved; skin superficial symptoms: improved; use of topical corticosteroids: improved |
| 82 Togni et al. 2014 | randomised controlled | Bosexil, Boswellia serrata resin extract with lecithin; vs. Placebo and Vaccinium myrtillus seed oil | improvement of scales in psoriasis: improved (70% of cases); improvement of erythema in psoriasis: improved (50% of cases); improvement of itch in eczema: improved (60% of cases) |
| 144 Mustafa et al. 2025 | review | Boswellic acids as natural compound; vs. Standard therapies or biologics | PASI score: improved |
| 150 Khalifa et al. 2023 | review | Frankincense (resin of Boswellia sacra) and its constituents | effects against skin disorders: improved |
Further studies in this area: 157
Frankincense (Boswellia) and Respiratory Tract: Human Studies
A meta-analysis of herbal asthma remedies cited a single study with boswellia as evidence of better lung function 22. In moderate COVID-19, oxygen saturation rose more with a syrup containing boswellic acids than with placebo, and the hospital stay was shorter 63. A mixture of Boswellia serrata and Aegle marmelos extract improved asthma symptoms and emotional function more than placebo in a randomized study 80. In a non-randomized study, a capsule mixture of Boswellia serrata, Curcuma longa and licorice lowered leukotriene C4 in plasma more than placebo 85. The respiratory studies tested almost only mixtures with other plants; it remains unclear how much frankincense contributes on its own.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 12 Efferth et al. 2022 | review | Frankincense (Boswellia spp.) and its phytochemical ingredients; vs. no uniform comparison reported | efficacy against asthma: improved |
| 22 Clark et al. 2010 | review | Boswellia frankincense among 20 herbal preparations; vs. Placebo in randomised controlled trials | Improvement in lung function (FEV1): improved |
| 63 Barzin et al. 2022 | randomised controlled · 47 participants | Inflawell® syrup, Boswellia extract enriched for boswellic acids; until discharge (length of hospitalization); vs. placebo plus standard of care | oxygen saturation: improved (P < 0.0001) |
| 105 De et al. 2023 | case-control study · 60 participants | Oral supplement with Ribes nigrum, Boswellia serrata, bromelain, vitamin D; 1 dose for 30 days or 2 doses daily for 15 days; 15 or 30 days; vs. control with nasal steroids only | nasal findings (mucosal hyperemia, rhinorrhea): improved (statistically significant differences from the control) |
| 139 Koshak et al. 2019 | cross-sectional study | Boswellia sacra (olibanum) among other herbal medicines | association asthma and herbal medicine intake: unclear (p=0.001) |
| 156 Wieczfinska et al. 2020 | review | Boswellic acid alongside other plant agents | Anti-inflammatory effect in lung disease models: improved |
Frankincense (Boswellia), Tolerability and Safety: Human Studies
Several controlled studies are available on the tolerability of boswellia preparations, which predominantly show no differences from placebo or comparison treatments in adverse events and safety parameters 1476267. Laboratory values such as blood count, serum chemistry and urine parameters also remained without abnormalities in several randomized controlled studies 4346495354. One randomized controlled study reported mild gastrointestinal complaints under a standardized Boswellia serrata extract in patients with brain tumors undergoing radiotherapy 65. In ankle sprain, Casperome was well tolerated in a non-randomized study 83. A systematic review described boswellic acids as well tolerated in radiation-induced brain edema, most commonly with mild gastrointestinal complaints 9. Tolerability was predominantly investigated for standardized extracts and capsules with resin; such data are still pending for essential oil and ointments.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Zhang et al. 2025 | meta-analysis · 4,599 participants | Boswellia (form not specified); vs. Placebo | Adverse events (No supplement was associated with increased adverse events compared to placebo) |
| 2 Del et al. 2017 | systematic review · 1,741 participants | Oral herbal medicines, including Boswellia serrata; vs. placebo or valdecoxib | adverse events |
| 3 Inprasit et al. 2026 | meta-analysis · 1,633 participants | Boswellia serrata (BS) and mixture with Curcuma longa; vs. Placebo and other intervention groups | Adverse events (No significant differences in adverse events were observed among all comparisons.) |
| 5 Bannuru et al. 2018 | meta-analysis · 1,009 participants | Boswellia and curcuminoid formulations; vs. Placebo or NSAIDs | Safety outcomes |
| 7 Yu et al. 2020 | meta-analysis · 545 participants | Boswellia serrata or its extract; recommended treatment duration at least 4 weeks; vs. Placebo or western medicine | Safety |
| 9 Dejonckheere et al. 2025 | review · 130 participants | Boswellic acid (BA), available as over-the-counter dietary supplement; not reported; optimal dosing unknown; not reported; vs. Corticosteroids as first-line standard; no uniform control | tolerability of boswellic acid (Tolerability of BA was favorable, with mild gastrointestinal discomfort being reported most frequently) |
| 10 Diantini et al. 2023 | systematic review | Plant-based add-on therapies, including Boswellia carterii; vs. Add-on therapy versus control/standard therapy | safety of the plant (The safety of the plant has been confirmed.) |
| 12 Efferth et al. 2022 | review | Frankincense (Boswellia spp.) and its phytochemical ingredients; vs. no uniform comparison reported | adverse side effects (only mild adverse side effects) |
Further studies in this area: 17 20 23 29 31 36 43 46 47 49 51 53 54 61 62 65 67 71 74 81 83 84 90 92 93 94 99 101 102 104 106 107 108 111 112 113 114 117 118 119 121 124 127 130 136 138 139 143 144 145 147 155 158 161 162
Frankincense (Boswellia): Further Outcomes in Studies
Orally disintegrating tablets with frankincense extract reduced the size of mouth ulcers (aphthae) and relieved their pain more than placebo 78; in healthy individuals, a single dose of Boswellia serrata increased the pressure pain threshold 74. In diabetes, olibanum gum resin in a randomized study lowered fasting blood glucose, HbA1c, insulin and blood lipids more than placebo 47; two further randomized studies with gum resin found no difference from placebo 5657. A non-randomized study without placebo reported more favorable blood lipids and fructosamine 86. In heavy menstrual bleeding, frankincense oleoresin in addition to ibuprofen improved quality of life more than placebo 39. A mixture of Boswellia and turmeric extract relieved chronic low back pain more than placebo 40.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 8 Karimi et al. 2024 | meta-analysis · 287 participants | Boswellia serrata supplementation; vs. Placebo or control group | HbA1C: improved (SMD: -1.01; 95%CI: -1.55 to -0.46; P=0.00); Total cholesterol: improved (SMD: -0.44; 95%CI: -0.68 to -0.21; P=0.00); Triglycerides: improved (SMD: -0.42; 95%CI: -0.66 to -0.19); P=0.00) |
| 9 Dejonckheere et al. 2025 | review · 130 participants | Boswellic acid (BA), available as over-the-counter dietary supplement; not reported; optimal dosing unknown; not reported; vs. Corticosteroids as first-line standard; no uniform control | radiographic or clinical benefit in cerebral edema/radiation necrosis: improved (Roughly half of patients benefited from BA); dexamethasone tapering or avoidance: improved (about one third could successfully taper dexamethasone or prevent its long-term intake) |
| 10 Diantini et al. 2023 | systematic review | Plant-based add-on therapies, including Boswellia carterii; vs. Add-on therapy versus control/standard therapy | efficacy of add-on therapy: improved (best efficacy ... found in <i>A. paniculata</i>) |
| 11 Kaya et al. 2023 | meta-analysis | Aromatherapy mixture including boswellia oil; vs. Standard care or placebo | Labor pain intensity: improved |
| 12 Efferth et al. 2022 | review | Frankincense (Boswellia spp.) and its phytochemical ingredients; vs. no uniform comparison reported | efficacy against multiple sclerosis: improved; relief of plaque-induced gingivitis and pain: improved; brain tumor-related edema: improved |
| 13 Lopes-Júnior et al. 2021 | review | Boswellic acid (one included study); vs. no comparison reported | effectiveness for symptom clusters (one boswellic acid study): unclear |
| 15 Mahdian et al. 2020 | review | Boswellia species (frankincense), form not specified | Metabolic syndrome and related disorders: improved; Insulin resistance and blood glucose: improved; Blood pressure: improved |
| 17 Farzaei et al. 2017 | systematic review | Boswellia papyrifera (boswellic acid) among other medicinal plants | efficacy in MS symptoms: improved |
Further studies in this area: 23 29 31 32 33 38 39 44 47 50 51 55 56 61 63 64 65 66 67 68 69 70 73 74 76 77 78 86 89 90 93 95 97 99 101 102 103 104 106 108 110 112 113 114 115 116 117 118 120 122 123 124 125 126 127 128 129 130 131 132 133 134 135 138 139 141 142 148 149 150 151 154 155 160 162
4. How Is Frankincense (Boswellia) Dosed? Preparation, Dose and Duration in Studies
The studies predominantly tested orally ingested extracts with a stated content of boswellic acids, mostly from Boswellia serrata, as capsules or tablets 2938. For the skin, creams with boswellic acids 717282 and a preparation of Boswellia carteri for burn wounds 58 were investigated. During a prostate biopsy, anxiety decreased under frankincense scent, but not in the placebo group, and the pain was less than expected 32; a back massage with frankincense and myrrh oil increased well-being before a cardiac catheterization procedure, but not pain 41.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| Ayurvedic formulations SGCG and SGC, incl. Boswellia serrata extract | — | 24 weeks | 24 |
| Turmeric-Boswellia extract (TBE) | 1,000 mg | 6 hours | 25 |
| Rhuleave-K (TBF): formulation of turmeric and Boswellia serrata extracts in sesame oil | single dose of 1000 mg TBF | single dose, observation up to 6 hours postdose | 26 |
| BV-4051, Ayurvedic polyherbal formulation containing Boswellia | — | 14 days | 27 |
| Curamin capsules: 350 mg curcuminoids and 150 mg boswellic acid (Boswellia serrata) | one 500-mg capsule three times daily | 12 weeks | 28 |
| Boswellia serrata extract (BOSMAX®) | daily (amount not stated) | 90 days | 29 |
| NXT15906F6 (TamaFlex) and CLBS blend (C. longa + Boswellia serrata) | 250 mg NXT15906F6 or 1000 mg CLBS daily after breakfast | 30 days | 30 |
| Mouthwash with frankincense extract (FR), also combined with Zataria multiflora (ZM) | not reported | 21 days (measurements days 1, 14, 21) | 31 |
| frankincense aromatherapy via nebulizer | — | during the procedure | 32 |
| frankincense-based herbal product (FHP) | — | 4 weeks, follow-up 2 weeks after treatment completion | 33 |
| Flogostop Duo (Boswellia serrata, bromelain, zinc, magnesium, honey, Lactobacillus) | — | 20 days (TG1) or 30 days (TG2) | 34 |
| MSM plus boswellic acids (MEBAGA) versus glucosamine sulfate | 5 g MSM and 7.2 mg boswellic acids daily | 60 days treatment, follow-up at 2 and 6 months | 35 |
| Boswellia serrata extract Boswelan (PS0201Bo), capsules | 3×2 capsules/day of 400 mg each | 52 weeks | 36 |
| F-BSE: bioavailability-enhanced full-spectrum Boswellia serrata oleo-gum resin extract; C-BSE co-delivered with curcumin | 400 mg/day | 28 days | 37 |
| Boswellin® Super, standardized Boswellia serrata gum resin extract, 30% 3-acetyl-11-keto-β-boswellic acid | 150 mg or 300 mg twice daily | 90 days | 38 |
5. Is Frankincense (Boswellia) Safe? Side Effects in Studies
Laboratory values such as blood count, serum chemistry and urine parameters remained without abnormalities in several randomized controlled trials 4346495354. One randomized controlled trial reported mild gastrointestinal complaints under a standardized Boswellia serrata extract in patients with brain tumors undergoing radiotherapy 65.
| Study | Reported side effects |
|---|---|
| 1 Zhang et al. 2025 | No increased adverse events versus placebo |
| 2 Del et al. 2017 | secondary outcome: adverse events |
| 3 Inprasit et al. 2026 | No significant differences in adverse events among all comparisons |
| 5 Bannuru et al. 2018 | No significant difference vs placebo in safety outcomes |
| 7 Yu et al. 2020 | described as safe, no figures |
| 9 Dejonckheere et al. 2025 | Tolerability favourable; mostly mild gastrointestinal discomfort |
| 12 Efferth et al. 2022 | only mild adverse side effects in toxicology and clinical trials |
| 14 Holleran et al. 2020 | Long-term effects and safety not established |
| 16 Liu et al. 2018 | No differences versus placebo for safety outcomes, except diacerein |
| 17 Farzaei et al. 2017 | Herbal medicines mostly well tolerated, adverse effects mild to moderate |
| 20 Posadzki et al. 2013 | Minor adverse effects reported for Boswellia serrata |
| 22 Clark et al. 2010 | Adverse effects were a secondary outcome but not reported |
6. What Remains Open: Limits of the Evidence
- Most studies are small and short and often tested brand-name extracts such as Aflapin, Boswellin Super or Casperome 384351; larger and longer studies are still pending.
- Regarding the tolerability of essential oil, ointments and non-standardized resin preparations, larger studies are still pending.
- It remains open which form and which boswellic acid content are decisive for which application.
- For Crohn's disease, a hint from a review 14 is contrasted by a placebo study that found no advantage in maintaining remission 36.
7. Bottom Line: What Is Established About Frankincense (Boswellia)
Frankincense is the gum resin of trees of the genus Boswellia. Studies in humans show, for orally ingested extracts with a stated content of boswellic acids, mostly from Boswellia serrata, improvements in knee osteoarthritis and inflammatory blood values 1267293843. For irritable bowel syndrome and acute diarrhea, there are initial hints from small studies 5161.
Many studies are small and short; some tested combination preparations whose result does not apply to frankincense alone. For essential oil, ointments and non-standardized resin preparations, larger studies are still pending.
Frequently Asked Questions
How well has Frankincense (Boswellia) been studied in humans?
We evaluated 215 human studies on Frankincense (Boswellia), including 94 randomised controlled trials and 17 meta-analyses or systematic reviews; the controlled studies include 7,221 participants in total. As of 9 October 2026.
Does Frankincense (Boswellia) help with joints and musculoskeletal system? What the studies show
Does Frankincense (Boswellia) help with inflammatory processes? What the studies show
Does Frankincense (Boswellia) help with gut? What the studies show
Does Frankincense (Boswellia) help with skin? What the studies show
Does Frankincense (Boswellia) help with respiratory tract? What the studies show
Does Frankincense (Boswellia) help with tolerability and safety? What the studies show
Which forms of frankincense were investigated in the studies?
Most frequently, orally ingested extracts with a stated content of boswellic acids were tested, mostly from Boswellia serrata, as capsules or tablets 2938. For the skin, creams with boswellic acids 717282 and a preparation of Boswellia carteri for burn wounds 58 were investigated. During a prostate biopsy, anxiety decreased under frankincense scent, but not in the placebo group, and the pain was less than expected 32; a back massage with frankincense and myrrh oil increased well-being before a cardiac catheterization procedure, but not pain 41.
What do the studies show for joint complaints?
In knee osteoarthritis, Boswellia showed improvements in pain, stiffness and function in several controlled studies and meta-analyses 12672938. The WOMAC total score and walking distance also improved in controlled studies 293843. One meta-analysis found no confirmed difference in WOMAC and pain across all comparisons, but lower WOMAC values compared with placebo 4.
How tolerable is frankincense?
Several controlled studies reported no differences from placebo or comparator treatments in adverse events and safety parameters 1476267. Laboratory values such as blood count, serum chemistry and urine parameters remained without abnormalities in several randomized controlled trials 4346495354. One randomized controlled trial reported mild gastrointestinal complaints under a standardized Boswellia serrata extract in patients with brain tumors undergoing radiotherapy 65.
Are there studies on inflammatory bowel diseases?
A systematic review saw hints of efficacy of Boswellia resin extract in Crohn's disease, mostly from small individual studies 14; another found the best evidence in Crohn's disease for wormwood 19. A randomized controlled trial in patients with Crohn's disease in remission found no difference in remission rate and time to relapse 36. In collagenous colitis, remission under Boswellia extract was more frequent per protocol than under placebo, with no confirmed difference in the analysis of all participants 68.
What should be considered with combination preparations?
Several controlled studies tested mixtures, for example with turmeric, ginger, methylsulfonylmethane or collagen 242526354852. With such combination preparations, the contribution of frankincense cannot be separated. Brand-name extracts such as Aflapin, Boswellin Super or Casperome (in lecithin form), by contrast, are preparations from Boswellia alone 384351.
Sources
- 1Zhang Y, Gui Y, Adams R, Farragher J, Itsiopoulos C, Bow K et al. · 2025
- 2Del Grossi Moura M, Lopes LC, Biavatti MW, Kennedy SA, de Oliveira E Silva MC, Silva MT et al. · 2017
- 3Inprasit C, Bunyamahote S, Boonpattharatthiti K, Thimkorn P, Intakhiao S, Dhippayom T · 2026
- 4Dalmonte T, Andreani G, Rudelli C, Isani G · 2024
- 5Bannuru RR, Osani MC, Al-Eid F, Wang C · 2018
- 6
- 7Yu G, Xiang W, Zhang T, Zeng L, Yang K, Li J · 2020
- 8Karimi M, Vakili K, Rashidian P, Razavi-Amoli SK, Akhbari M, Kazemi K · 2024
- 9Dejonckheere CS, Scafa D, Käsmann L, Zeyen T, Potthoff AL, Schäfer N et al. · 2025
- 10Diantini A, Febriyanti RM, Levita J · 2023
- 11Kaya A, Yeşildere Sağlam H, Karadağ E, Gürsoy E · 2023
- 12Efferth T, Oesch F · 2022
- 13Lopes-Júnior LC, Urbano IR, Schuab SIPC, Pessanha RM, Rosa GS, Lima RAG · 2021
- 14Holleran G, Scaldaferri F, Gasbarrini A, Gasbarrini A, Currò D · 2020
- 15Mahdian D, Abbaszadeh-Goudarzi K, Raoofi A, Dadashizadeh G, Abroudi M, Zarepour E et al. · 2020
- 16Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ · 2018
- 17Farzaei MH, Shahpiri Z, Bahramsoltani R, Nia MM, Najafi F, Rahimi R · 2017
- 18Fusini F, Bisicchia S, Bottegoni C, Gigante A, Zanchini F, Busilacchi A · 2016
- 19Langhorst J, Wulfert H, Lauche R, Klose P, Cramer H, Dobos GJ et al. · 2015
- 20Posadzki P, Watson LK, Ernst E · 2013
- 21Di Lorenzo C, Dell'Agli M, Badea M, Dima L, Colombo E, Sangiovanni E et al. · 2013
- 22Clark CE, Arnold E, Lasserson TJ, Wu T · 2010
- 23Ernst E · 2008
- 24Chopra A, Saluja M, Tillu G, Sarmukkaddam S, Venugopalan A, Narsimulu G et al. · 2013
- 25
- 26Rudrappa GH, Murthy M, Saklecha S, Kumar Kare S, Gupta A, Basu I · 2022
- 27Chitre D, Nadkarni S, Jagtap N, Tulle R, Gitte A, Rahate P et al. · 2023
- 28Haroyan A, Mukuchyan V, Mkrtchyan N, Minasyan N, Gasparyan S, Sargsyan A et al. · 2018
- 29Jayaram M, Kim J, Baek KS, Jung H, Kim J, M K P et al. · 2025
- 30Prasad N, Vinay V, Srivastava A · 2023
- 31Khoshbakht Z, Khashabi E, Khodaie L, Torbati M, Lotfipour F, Hamishehkar H · 2019
- 32Saylam B, Nebioğlu A, Aydınlı B, Efesoy O, Bozlu M, Akbay E · 2026
- 33Karbalaiee M, Daneshpajooh A, Khanjani N, Sohbati S, Mehrabani M, Mehrbani M et al. · 2023
- 34Della Volpe A, De Luca P, De Lucia A, Martines F, Piroli P, D'Ascanio L et al. · 2022
- 35Notarnicola A, Maccagnano G, Moretti L, Pesce V, Tafuri S, Fiore A et al. · 2016
- 36Holtmeier W, Zeuzem S, Preiss J, Kruis W, Böhm S, Maaser C et al. · 2011
- 37Mamatha K, Prabhakaran P, Syam Das S, Kanjoormana Aryan M, Thomas J · 2025
- 38Majeed A, Majeed S, Satish G, Manjunatha R, Rabbani SN, Patil NVP et al. · 2024
- 39Eshaghian R, Mazaheri M, Ghanadian M, Rouholamin S, Feizi A, Babaeian M · 2019
- 40Majumdar A, Prasad MAVV, Gandavarapu SR, Reddy KSK, Sureja V, Kheni D et al. · 2025
- 41Özdemir Ü, Taşcı S, Döner A, Özdemir Alkanat H, İnanç MT · 2024
- 42Faraji A, Aghdaki M, Hessami K, Hosseinkhani A, Roozmeh S, Asadi N et al. · 2021
- 43Kumar B, Ghaytidak AB, Pandey AK, Somepalli RR, Sarda P, Raychaudhuri SP et al. · 2025
- 44Baram SM, Karima S, Shateri S, Tafakhori A, Fotouhi A, Lima BS et al. · 2019
- 45Karimifar M, Soltani R, Hajhashemi V, Sarrafchi S · 2017
- 46Sengupta K, Alluri KV, Satish AR, Mishra S, Golakoti T, Sarma KV et al. · 2008
- 47A Randomized Clinical Trial Study: Anti-Oxidant, Anti-hyperglycemic and Anti-Hyperlipidemic Effects of Olibanum Gum in Type 2 Diabetic PatientsAzadmehr A, Ziaee A, Ghanei L, Fallah Huseini H, Hajiaghaee R, Tavakoli-Far B et al. · 2014
- 48Mazurov VI, Belyaeva IB, Trofimov EA, Itskovich IE, Burulev AL · 2023
- 49Karlapudi V, Sunkara KB, Konda PR, Sarma KV, Rokkam MP · 2023
- 50Reis D, Throne T, Keller J, Koffel C, Chen T, Young-McCaughan S · 2023
- 51Riva A, Giacomelli L, Togni S, Franceschi F, Eggenhoffner R, Zuccarini MC et al. · 2019
- 52Giacosa A, Riva A, Petrangolini G, Allegrini P, Fazia T, Bernardinelli L et al. · 2022
- 53Vishal AA, Mishra A, Raychaudhuri SP · 2011
- 54Sengupta K, Krishnaraju AV, Vishal AA, Mishra A, Trimurtulu G, Sarma KV et al. · 2010
- 55Shateri S, Khatami SH, Ehtiati S, Talebzadeh MR, Nikakhtar S, Parvar MH et al. · 2025
- 56Mehrzadi S, Tavakolifar B, Huseini HF, Mosavat SH, Heydari M · 2018
- 57The Efficacy of Boswellia Serrata Gum Resin for Control of Lipid Profile and Blood Glucose in Diabetic PatientsMehrzadi S, Tavakolifar B, Huseini HF, Mosavat SH, Heydari M · 2016
- 58Badr P, Afsharypuor S, Tohidinik HR, Mohammadi AA, Daneshamouz S · 2023
- 59Salter D, Yalamanchi H, Yalamanchi A, Yalamanchi A · 2025
- 60Giacosa A, Barrile GC, Perna S, Rondanelli M · 2024
- 61Giacosa A, Riva A, Petrangolini G, Allegrini P, Fazia T, Bernardinelli L et al. · 2022
- 62Majeed M, Majeed S, Narayanan NK, Nagabhushanam K · 2019
- 63Barzin Tond S, Balenci L, Khajavirad N, Salehi M, Tafakhori A, Shahmohammadi MR et al. · 2022
- 64
- 65Kirste S, Treier M, Wehrle SJ, Becker G, Abdel-Tawab M, Gerbeth K et al. · 2011
- 66The Efficacy of Kundur (Boswellia serrata Roxb. Ex Colebr.) in Vulvovaginal Candidiasis: A Randomized Control TrialInamdar NK, Roqaiya M, Husain N, Ahmed K, Baig S · 2023
- 67Moein P, Abbasi Fard S, Asnaashari A, Baratian H, Barekatain M, Tavakoli N et al. · 2013
- 68Madisch A, Miehlke S, Eichele O, Mrwa J, Bethke B, Kuhlisch E et al. · 2007
- 69Donovan EK, Kekes-Szabo S, Lin JC, Massey RL, Cobb JD, Hodgin KS et al. · 2021
- 70Effect of 4 weeks of frankincense consumption on explicit motor memory and serum BDNF in elderly menAsadı E, Shahabı Kaseb MR, Zeıdabadı R, Hamedınıa MR · 2019
- 71Calzavara-Pinton P, Zane C, Facchinetti E, Capezzera R, Pedretti A · 2010
- 72Pedretti A, Capezzera R, Zane C, Facchinetti E, Calzavara-Pinton P · 2010
- 73Hammer S, Reiser M, Bader M, Pannold J, Moser A, Niederer M et al. · 2026
- 74Prabhavathi K, Chandra US, Soanker R, Rani PU · 2014
- 75Mohsenzadeh A, Karimifar M, Soltani R, Hajhashemi V · 2023
- 76Pérez-Piñero S, Muñoz-Carrillo JC, Victoria-Montesinos D, García-Muñoz AM, Andreu-Caravaca L, Gómez M et al. · 2023
- 77Meshkat S, Mahmoodi Baram S, Rajaei S, Mohammadian F, Kouhestani E, Amirzargar N et al. · 2022
- 78Soltani R, Saberi Z, Ghanadian SM, Taheri A, Entezarhojjat A · 2022
- 79Kulkarni PD, Damle ND, Singh S, Yadav KS, Ghante MR, Bhaskar VH et al. · 2020
- 80
- 81Clinical evaluation of safety and efficacy of Boswellia-based cream for prevention of adjuvant radiotherapy skin damage in mammary carcinoma: a randomized placebo controlled trialTogni S, Maramaldi G, Bonetta A, Giacomelli L, Di Pierro F · 2015
- 82Togni S, Maramaldi G, Di Pierro F, Biondi M · 2014
- 83Effectiveness of a novel boswellic acids delivery form (Casperome®) in the management of grade II ankle sprains due to sport trauma - a registry studyFeragalli B, Ippolito E, Dugall M, Cacchio M, Belcaro G, Cesarone MR et al. · 2017
- 84Supplementation with a lecithin-based delivery form of Boswellia serrata extract (Casperome®) controls symptoms of mild irritable bowel syndromeBelcaro G, Gizzi G, Pellegrini L, Corsi M, Dugall M, Cacchio M et al. · 2017
- 85Houssen ME, Ragab A, Mesbah A, El-Samanoudy AZ, Othman G, Moustafa AF et al. · 2010
- 86Ahangarpour A, Heidari H, Fatemeh RA, Pakmehr M, Shahbazian H, Ahmadi I et al. · 2014
- 87Gupta PK, Samarakoon SM, Chandola HM, Ravishankar B · 2011
- 88A novel lecithin based delivery form of Boswellic acids (Casperome®) for the management of osteo-muscular pain: a registry study in young rugby playersFranceschi F, Togni S, Belcaro G, Dugall M, Luzzi R, Ledda A et al. · 2016
- 89Khamaal Hussein Abod Al-Khafaji, Zahraa Mohammed Fakheir, Shaimaa Mohammed Ali Jasim · 2025
- 90Valente IVB, Garcia D, Abbott A, Spruill L, Siegel J, Forcucci J et al. · 2024
- 91Barzin Tond S, Abolghasemi S, Khatami SH, Ehtiati S, Zarei T, Shateri S et al. · 2025
- 92Henrotin Y, Dierckxsens Y, Delisse G, Seidel L, Albert A · 2021
- 93Passaro M, Mainini G, Ambrosio F, Sgambato R, Balbi G · 2017
- 94Henrotin Y, Dierckxsens Y, Delisse G, Maes N, Albert A · 2022
- 95El-Khouly FE, Adil SM, Wiese M, Hulleman E, Hendrikse NH, Kaspers GJL et al. · 2021
- 96Ait Abdellah S, Gal C, Leblanc A, Trouvin AP, Perrot S · 2021
- 97
- 98Żęgota Z, Goździk J, Głogowska-Szeląg J · 2021
- 99Giglio M, Mattia C, Sansone P, Finco G, Sardo S, Sofia M et al. · 2025
- 100
- 101Upadhyay R, Elguindy ANM, Salts L, Donovan K, Sengupta S, Wang K et al. · 2025
- 102Bonucci M, Fuggetta MP, Anelli L, Giannarelli D, Fiorentini C, Ravagnan G · 2025
- 103Dyer J, Cleary L, McNeill S, Ragsdale-Lowe M, Osland C · 2016
- 104Presicce F, Barrese F, Cantiani A, Filianoti A, Tuzzolo D, Di Palma P et al. · 2022
- 105De Luca P, D'Ascanio L, Cingolani C, Latini G, Grigaliute E, Di Mauro P et al. · 2023
- 106Belcaro G, Dugall M, Luzzi R, Hosoi M, Ledda A, Feragalli B et al. · 2018
- 107Movardol® (N-acetylglucosamine, Boswellia serrata, ginger) supplementation in the management of knee osteoarthritis: preliminary results from a 6-month registry studyBolognesi G, Belcaro G, Feragalli B, Cornelli U, Cotellese R, Hu S et al. · 2016
- 108Cominacini M, Valenti MT, Braggio M, Caramori A, Vedovi E, Dalle Carbonare L · 2025
- 109Desideri I, Lucidi S, Francolini G, Meattini I, Ciccone LP, Salvestrini V et al. · 2022
- 110Managing ulcerative colitis in remission phase: usefulness of Casperome®, an innovative lecithin-based delivery system of Boswellia serrata extractPellegrini L, Milano E, Franceschi F, Belcaro G, Gizzi G, Feragalli B et al. · 2016
- 111Kim SK, Jayachandran V, Vo TS, Wijesekara I · 2025
- 112Sibona M, Destefanis P, Agnello M, Lillaz B, Giuliano M, Cai T et al. · 2020
- 113Stürner KH, Stellmann JP, Dörr J, Paul F, Friede T, Schammler S et al. · 2018
- 114Schettino MT, Vastarella MG, Riemma G, Dores E, Turco F, De Franciscis P · 2025
- 115Di Vico T, Durante J, Polito C, Tognarelli A, Canale D, Caglieresi C et al. · 2020
- 116Stürner KH, Werz O, Koeberle A, Otto M, Pless O, Leypoldt F et al. · 2020
- 117Desideri I, Francolini G, Becherini C, Terziani F, Delli Paoli C, Olmetto E et al. · 2017
- 118Di Pierro F, Simonetti G, Petruzzi A, Bertuccioli A, Botta L, Bruzzone MG et al. · 2019
- 119Mocci G, Orrù G, Elisei W, Usai Satta P, Onidi FM, Tursi A · 2025
- 120Tarumi W, Shinohara K · 2020
- 121Five Herbs Plus Thiamine Reduce Pain and Improve Functional Mobility in Patients With Pain: A Pilot StudyHedaya R · 2017
- 122Kulkarni PD, Damle ND, Hingorani L, Bhaskar VH, Ghante MR, Patil A et al. · 2021
- 123Lampl C, Haider B, Schweiger C · 2012
- 124
- 125Paulis G, De Giorgio G · 2022
- 126Baker MJ, Harrison AR, Lee MS · 2023
- 127
- 128Effect of extract from Boswellia serrata gum resin on decrease of GAD65 autoantibodies in a patient with Latent Autoimmune Diabetes in AdultsFranić Z, Franić Z, Vrkić N, Gabaj NN, Petek I · 2020
- 129Reis D, Jones TT · 2018
- 130Xia D, Lou W, Fung KM, Wolley CL, Suhail MM, Lin HK · 2017
- 131Allen J, Shekelle PG, Booth M · 2026
- 132Harrathi H, Al-Qasimi A, Dridi M, Al-Sheerawi N, Jlassi M · 2026
- 133Giacosa A, Barrile GC, Gasparri C, Perna S, Rondanelli M · 2025
- 134Cindolo L, Fabiani A, Vitelli D, Cianci F, Gatti L, Ghidini N et al. · 2023
- 135Guarino O, Iovino C, Di Iorio V, Rosolia A, Schiavetti I, Lanza M et al. · 2022
- 136Italiano G, Raimondo M, Giannetti G, Gargiulo A · 2020
- 137Giacosa A, Riva A, Petrangolini G, Allegrini P, Fazia T, Bernardinelli L et al. · 2020
- 138Alshammari MA, Hassan A, Alsaihati AS, Aldera FH, Alaithan HS · 2020
- 139
- 140Perera PK, Perera M, Kumarasinghe N · 2014
- 141PREPARATION FOR WEIGHT LOSS MANAGEMENTCHATTERJI ARUN K · 2011
- 142Siti HN, Lua PL, Taib MNA, Zulfarina MS, Nordin ML, Sharifudin MA · 2026
- 143Chaudhary S, Sharma S, Fuloria S · 2025
- 144Mustafa AM, Atwa AM, Elgindy AM, Alkabbani MA, Ibrahim KM, Esmail MM et al. · 2025
- 145Dzwonkowski M, Bahirwani J, Rollins S, Muratore A, Christian V, Schneider Y · 2025
- 146Mittal V, Sharma A, Barak A, Singhal A · 2025
- 147Verma S, Panchpuri M, Dwibedi V, Rath SK, Devi A · 2025
- 148Febriyanti RM, Levita J, Diantini A · 2024
- 149Mobasheri L, Ahadi M, Beheshti Namdar A, Alavi MS, Bemidinezhad A, Moshirian Farahi SM et al. · 2023
- 150Frankincense of Boswellia sacra: Traditional and modern applied uses, pharmacological activities, and clinical trialsKhalifa SAM, Kotb SM, El-Seedi SH, Nahar L, Sarker SD, Guo Z et al. · 2023
- 151Marchesi N, Govoni S, Allegri M · 2022
- 152Sethi V, Garg M, Herve M, Mobasheri A · 2022
- 153Żęgota Z, Goździk J, Głogowska-Szeląg J · 2021
- 154Gomaa AA, Farghaly HA, Abdel-Wadood YA, Gomaa GA · 2021
- 155Gomaa AA, Mohamed HS, Abd-Ellatief RB, Gomaa MA · 2021
- 156Wieczfinska J, Sitarek P, Kowalczyk T, Skała E, Pawliczak R · 2020
- 157
- 158Liu X, Eyles J, McLachlan AJ, Mobasheri A · 2018
- 159Henrotin Y, Mobasheri A · 2018
- 160Mojaverrostami S, Bojnordi MN, Ghasemi-Kasman M, Ebrahimzadeh MA, Hamidabadi HG · 2018
- 161Vaishya R, Agarwal AK, Shah A, Vijay V, Vaish A · 2018
- 162Riva A, Allegrini P, Franceschi F, Togni S, Giacomelli L, Eggenhoffner R · 2017
- 163Parian A, Limketkai BN · 2016
- 164Herbal and plant therapy in patients with inflammatory bowel diseaseTriantafyllidi A, Xanthos T, Papalois A, Triantafillidis JK · 2015
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.